Skip to Content
Merck
  • Cell culture studies of a carborane cholesteryl ester with conventional and PEG liposomes.

Cell culture studies of a carborane cholesteryl ester with conventional and PEG liposomes.

Drug delivery (2003-01-30)
G F Peacock, B Ji, C K Wang, D R Lu
ABSTRACT

A new cholesterol-carborane conjugate (BCH) has been synthesized as a potential targeting agent for boron neutron capture therapy (BNCT) of cancers. The compound is extremely water insoluble and was formulated in two liposomal formulations to determine if the compound could be adequately taken up by 9L rat glioma cells in cell culture. Several factors potentially affecting the cellular uptake were evaluated, such as concentration of BCH in the incubation medium, incubation time, cell confluence, and the addition of polyethylene glycol (PEG) phospholipids to the liposomal formulation. The studies indicated that the cellular uptakes of BCH in the conventional and PEG liposomal formulations were 49.1 and 45.9 microg boron/g cells, respectively. Therefore, this compound, formulated in both liposomal formulations, delivered sufficient levels of boron to cancer cells in vitro, indicating that BCH is a promising approach for use in BNCT. The uptake appeared to depend upon BCH concentration in the media as well as the confluence of the cells. The greater boron uptake by nonconfluent cells indicated that active growth of cells was a factor in the uptake of this compound.

MATERIALS
Product Number
Brand
Product Description

Avanti
18:1 PEG1000 PE, Avanti Polar Lipids 880730P, powder
Avanti
18:1 PEG550 PE, Avanti Polar Lipids 880530O
Avanti
16:0 PEG350 PE, Avanti Polar Lipids 880400P, powder
Avanti
18:1 PEG1000 PE, Avanti Polar Lipids 880730C
Avanti
16:0 PEG550 PE, Avanti Polar Lipids 880500P, powder
Avanti
18:1 PEG550 PE, Avanti Polar Lipids 880530C
Avanti
16:0 PEG750 PE, Avanti Polar Lipids 880600P, powder
Avanti
18:1 PEG750 PE, Avanti Polar Lipids 880630O
Avanti
18:1 PEG350 PE, Avanti Polar Lipids 880430O